418 related articles for article (PubMed ID: 10789605)
1. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
[TBL] [Abstract][Full Text] [Related]
2. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
3. Virological response to protease inhibitor therapy in an HIV clinic cohort.
Staszewski S; Miller V; Sabin C; Carlebach A; Berger AM; Weidmann E; Helm EB; Hill A; Phillips A
AIDS; 1999 Feb; 13(3):367-73. PubMed ID: 10199227
[TBL] [Abstract][Full Text] [Related]
4. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B
J Acquir Immune Defic Syndr; 1999 Oct; 22(2):132-8. PubMed ID: 10843526
[TBL] [Abstract][Full Text] [Related]
5. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Mocroft A; Phillips AN; Miller V; Gatell J; van Lunzen J; Parkin JM; Weber R; Roge B; Lazzarin A; Lundgren JD;
AIDS; 2001 Jan; 15(2):201-9. PubMed ID: 11216928
[TBL] [Abstract][Full Text] [Related]
6. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
7. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
8. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
9. Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A; Ruiz L; Reiss P; Ledergerber B; Katlama C; Lazzarin A; Goebel FD; Phillips AN; Clotet B; Lundgren JD;
AIDS; 2003 Aug; 17(12):1741-51. PubMed ID: 12891060
[TBL] [Abstract][Full Text] [Related]
10. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
Annan NT; Nelson M; Mandalia S; Bower M; Gazzard BG; Stebbing J
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):140-6. PubMed ID: 19352201
[TBL] [Abstract][Full Text] [Related]
11. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
[TBL] [Abstract][Full Text] [Related]
13. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
14. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor.
Mocroft A; Gill MJ; Davidson W; Phillips AN
AIDS; 1998 Nov; 12(16):2161-7. PubMed ID: 9833857
[TBL] [Abstract][Full Text] [Related]
15. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
16. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.
Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M
Arch Intern Med; 2000 Apr; 160(8):1134-40. PubMed ID: 10789606
[TBL] [Abstract][Full Text] [Related]
17. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
[TBL] [Abstract][Full Text] [Related]
18. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.
Touloumi G; Paparizos V; Sambatakou H; Katsarou O; Chrysos G; Kordossis T; Antoniadou A; Hatzitheodorou H; Stavrianeas N; Gargalianos P; Karafoulidou A; Lazanas M; Giamarelou H; Hatzakis A
HIV Clin Trials; 2001; 2(1):6-16. PubMed ID: 11590509
[TBL] [Abstract][Full Text] [Related]
19. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
Fätkenheuer G; Theisen A; Rockstroh J; Grabow T; Wicke C; Becker K; Wieland U; Pfister H; Reiser M; Hegener P; Franzen C; Schwenk A; Salzberger B
AIDS; 1997 Nov; 11(14):F113-6. PubMed ID: 9386799
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.
d'Arminio Monforte A; Testa L; Adorni F; Chiesa E; Bini T; Moscatelli GC; Abeli C; Rusconi S; Sollima S; Balotta C; Musicco M; Galli M; Moroni M
AIDS; 1998 Sep; 12(13):1631-7. PubMed ID: 9764782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
